Acute myocardial infarction - The enduring challenge for cardiac protection and survival

Circulation Journal

Volumn 73, Issue 11, 2009, Pages 2000-2008

  Yasuda, Satoshi ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adrenomudullin; Microvasculature; Myocardial infarction; Pre hospital; Reperfusion

Indexed keywords

ADENOSINE; ADRENOMEDULLIN; AMIODARONE; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CREATINE KINASE; CREATINE KINASE MB; FIBRINOLYTIC AGENT; ICOSAPENTAENOIC ACID; NICORANDIL; NIFEKALANT; OMEGA 3 FATTY ACID; PLACEBO; REVIPARIN; RHO KINASE; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTIFICIAL EMBOLISM; BARE METAL STENT; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEFIBRILLATOR; DRUG ELUTING STENT; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HUMAN; IN-STENT RESTENOSIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REPERFUSION INJURY; RESUSCITATION; REVIEW; ST SEGMENT ELEVATION; TAKOTSUBO CARDIOMYOPATHY; THROMBECTOMY; THROMBUS ASPIRATION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOPULMONARY RESUSCITATION; EMERGENCY MEDICAL SERVICES; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY;

EID: 73249145598     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0655     Document Type: Review

References (98)

1. World Health Organization. Regions for health network in Europe: Actions towards health equity. http://www.euro.who.int/document/e89941.pdf (accessed 21 August, 2009).
2. Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, et al. Increasing incidence but decreasing mortality of acute myocardial infarction over 30 years in Japan: Report from the MIYAGI-AMI Registry Study. Circ J 2009 (in press).
3. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
4. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
5. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
6. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: The present and the future. J Am Coll Cardiol 2006; 48: 1-11.
7. Collinson PO, Hadcocks L, Foo Y, Rosalki SB, Stubbs PJ, Morgan SH, et al. Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998; 35: 380-386.
8. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: Review and clinical implications. J Am Coll Cardiol 2002; 40: 2065-2071.
9. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-1349.
10. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia: GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333-1341.
11. Kanna M, Nonogi H, Sumida H, Miyazaki S, Daikoku S, Yasuda S, et al. Usefulness of serum troponin T levels on day three or four in predicting survival after acute myocardial infarction. Am J Cardiol 2001; 87: 294-297.
12. Goodman SG, Steg PG, Eagle KA, Fox KA, López-Sendón J, Montalescot G, et al; GRACE Investigators. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006; 151: 654-660.
13. Hochholzer W, Buettner HJ, Trenk D, Laule K, Christ M, Neumann FJ, et al. New definition of myocardial infarction: Impact on long-term mortality. Am J Med 2008; 121: 399-405.
14. Sato H, Tateishi H, Uchida T. Takotsubo-type cardiomyopathy due to multivessel spasm. In: Kodama K, Haze K, Hon M, editors. Clinical aspect of myocardial injury: From ischemia to heart failure. Tokyo, Japan: Kagakuhyouronsha; 1990; 56-64.
15. Kawai S, Kitabatake A, Tomoike H, Takotsubo Cardiomyopathy Group. Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy. Circ J 2007; 71: 990-992.
16. Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, et al. Angina Pectoris-Myocardial Infarction Investigations in Japan. Transient left ventricular apical ballooning without coronary artery stenosis: A novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol 2001; 38: 11-18.
17. Kume T, Akasaka T, Kawamoto T, Yoshitani H, Watanabe N, Neishi Y, et al. Assessment of coronary microcirculation in patients with takotsubo-like left ventricular dysfunction. Circ J 2005; 69: 934-939.
18. Yoshida T, Hibino T, Kako N, Murai S, Oguri M, Kato K, et al. A pathophysiologic study of tako-tsubo cardiomyopathy with F-18 fluorodeoxyglucose positron emission tomography. Eur Heart J 2007; 28: 2598-2604.
19. Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Wright RS, et al. Systematic review: Transient left ventricular apical ballooning: A syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med 2004; 141: 858-865.
20. Kume T, Kawamoto T, Okura H, Toyota E, Neishi Y, Watanabe N, et al. Local release of catecholamines from the hearts of patients with tako-tsubo-like left ventricular dysfunction. Circ J 2008; 72: 106-108.
21. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
22. Yasuda S, Goto Y, Baba T, Satoh T, Sumida H, Miyazaki S, et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 2000; 36: 115-121.
23. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
24. Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: Where are the theories and trials leading us? Heart 2000; 83: 76-80.
25. Topol EJ. Validation of the early open infarct vessel hypothesis. Am J Cardiol 1993; 72: 40G-45G.
26. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110: e82-e292.
27. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no reflow' phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-228.
28. Poli A, Fetiveau R, Vandoni P, del Rosso G, D'Urbano M, Seveso G, et al. Integrated analysis of myocardial blush and ST-segment elevation recovery after successful primary angioplasty: Real-time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function. Circulation 2002; 106: 313-318.
29. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39: 591-597.
30. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-1508.
31. Braunwald E, Kloner RA. Myocardial reperfusion: A double-edged sword? J Clin Invest 1985; 76: 1713-1719.
32. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993; 21: 537-545.
33. Shimokawa H, Yasuda S. Myocardial ischemia: Current concepts and future perspectives. J Cardiol 2008; 52: 67-78.
34. Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB, et al. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion. J Am Coll Cardiol 2001; 37: 9-18.
35. Bahrmann P, Werner GS, Heusch G, Ferrari M, Poerner TC, Voss A, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 2007; 115: 600-608.
36. Arakawa K, Yasuda S, Hao H, Kataoka Y, Morii I, Kasahara Y, et al. Significant association between neutrophil aggregation in aspirated thrombus and myocardial damage in patients with ST-segment elevation acute myocardial infarction. Circ J 2009; 73: 139-144.
37. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade: Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
38. Matetzky S, Novikov M, Gruberg L, Freimark D, Feinberg M, Elian D, et al. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999; 34: 1932-1938.
39. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: The role of modulating inflammation. Circulation 2003; 108(Suppl 1): III-22-III-27.
40. Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, Goto Y, et al. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci (Lond) 2007; 112: 43-49.
41. Takeno M, Yasuda S, Otsuka Y, Morii I, Kawamura A, Yano K, et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: Potential association with C-reactive protein. Circ J 2008; 72: 415-419.
42. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
43. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-360.
44. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al; Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: A randomized controlled trial. JAMA 2005; 293: 1063-1072.
45. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: A comprehensive meta-analysis of randomized trials. Eur Heart J 2008; 29: 2989-3001.
46. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008; 358: 557-567.
47. De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis of randomized trials. Eur Heart J 2008; 29: 3002-3010.
48. Kotooka N, Otsuka Y, Yasuda S, Morii I, Kawamura A, Miyazaki S. Three cases of acute myocardial infarction due to coronary embolism: Treatment using a thrombus aspiration device. Jpn Heart J 2004; 45: 861-866.
49. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 2007; 50: 573-583.
50. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
51. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
52. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713.
53. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118: 1138-1145.
54. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
55. Shiroto T, Yasuda S, Tsuburaya T, Ito Y, Takahashi J, Ito K, et al. Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stent in pigs in vivo. J Am Coll Cardiol 2009 (in press).
56. Mori S, Yasuda S, Kataoka Y, Morii I, Kawamura A, Miyazaki S. Significant association of coronary artery calcification in stent delivery route with restenosis after sirolimus-eluting stent implantation. Circ J 2009; 73: 1856-1863.
57. Cannon RO 3rd. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005; 2: 88-94.
58. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J Am Coll Cardiol 2004; 44: 276-286.
59. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288.
60. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006; 24: 116-147.
61. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-1780.
62. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 2006; 295: 1519-1530.
63. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-446.
64. Shimokawa H, Vanhoutte PM. Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol 1989; 256: H968-H973.
65. Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006; 83(Suppl): 1477S-1482S.
66. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: Systematic review. BMJ 2008; 337: a2931.
67. Tsuburaya R, Yasuda S, Ito Y, Shiroto T, Gao J, Ito K, et al. Long-term treatment with eicosapentaenoic acid suppresses ischemia-induced ventricular fibrillation: Potential involvement of ATP-sensitive potassium (KATP) channel (abstract). Circulation 2008; 118(Suppl II):S-1137.
68. Yellon DM, Hausenloy DJ. Realizing the clinical potential of ischemic preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med 2005; 2: 568-575.
69. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: Opportunities and obstacles for survival signaling. Br J Pharmacol 2007; 152: 855-869.
70. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006; 101: 311-318.
71. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet 2007; 370: 1483-1493.
72. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
73. Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004; 109: 242-248.
74. Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol 2003; 285: H1506-H1514.
75. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101: 498-503.
76. Yasuda S, Miyazaki S, Nagaya N, Kataoka Y, Noguchi T, Morii I, et al. Feasibility of adrenomedullin infusion in patients with acute myocardial infarction -a possible cardioprotective therapy against ischemic injury (abstract). Circulation 2007; 116(Suppl II): II-3379.
77. Löwel H, Dobson A, Keil U, Herman B, Hobbs MS, Stewart A, et al. Coronary heart disease case fatality in four countries: A community study. The Acute Myocardial Infarction Register Teams of Auckland, Augsburg, Bremen, FINMONICA, Newcastle, and Perth. Circulation 1993; 88: 2524-2531.
78. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328-1428.
79. Takagi Y, Yasuda S, Takahashi J, Takeda M, Nakayama M, Ito K, et al. Importance of dual induction tests for coronary vasospasm and ventricular fibrillation in patients surviving out-of-hospital cardiac arrest. Circ J 2009; 73: 767-769.
80. O'Doherty M, Tayler DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res Ed) 1983; 286: 1405-1408.
81. Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from sudden cardiac arrest: The "chain of survival" concept: A statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association. Circulation 1991; 83: 1832-1847.
82. SOS-KANTO Study Group. Cardiopulmonary resuscitation by bystanders with chest compression only (SOS-KANTO): An observational study. Lancet 2007; 369: 920-926.
83. Iwami T, Kawamura T, Hiraide A, Berg RA, Hayashi Y, Nishiuchi T, et al. Effectiveness of bystander-initiated cardiac-only resuscitation for patients with out-of-hospital cardiac arrest. Circulation 2007; 116: 2900-2907.
84. Ewy GA. Cardiac arrest - guideline changes urgently needed. Lancet 2007; 369: 882-884.
85. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-890.
86. Takenaka K, Yasuda S, Miyazaki S, Kurita T, Sutani Y, Morii I, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J 2001; 65: 60-62.
87. Ohashi J, Yasuda S, Miyazaki S, Shimizu W, Morii I, Kurita T, et al. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride. J Cardiovasc Pharmacol 2006; 48: 274-279.
88. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-692.
89. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J 2006; 70: 442-446.
90. Yasuda S, Sawano H, Hazui H, Ukai K, Yokoyama H, Kada A, et al. High rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation treated with nifekalant hydrochloride: Report from J-PULSE registry. Jpn J Electrocardiol 2009; 29: 44-49.
91. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
92. Grzybowski M, Clements EA, Parsons L, Welch R, Tintinalli AT, Ross MA, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: A propensity analysis. JAMA 2003; 290: 1891-1898.
93. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996; 348: 771-775.
94. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000; 283: 2686-2692.
95. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al; Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: Data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.
96. Bonnefoy E, Steg PG, Boutitie F, Dubien PY, Lapostolle F, Roncalli J, CAPTIM Investigators. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: A 5-year follow-up. Eur Heart J 2009; 30: 1598-1606.
97. Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P. Development of systems of care for ST-elevation myocardial infarction patients: Executive summary. Circulation 2007; 116: 217-230.
98. Antman EM. Time is muscle: Translation into practice. J Am Coll Cardiol 2008; 52: 1216-1221.